Table 1.
Baseline characteristics
| MIL60 (n=253) | Bevacizumab (n=255) | All patients (n=508) | |
|---|---|---|---|
| Age (years) | |||
| Median (IQR, range) | 61.0 (13.0; 23-75) | 61.0 (11.0; 35-76) | 61.0 (12.0; 23-76) |
| < 60 | 114 (45.1%) | 111 (43.5%) | 225 (44.3%) |
| ≥ 60 | 139 (54.9%) | 144 (56.5%) | 283 (55.7%) |
| Sex | |||
| Male | 163 (64.4%) | 162 (63.5%) | 325 (64.0%) |
| Female | 90 (35.6%) | 93 (36.5%) | 183 (36.0%) |
| BMI (kg/m²) | |||
| Median (IQR, range) | 22.3 (4.1; 15.8-33.8) | 22.5 (3.8; 13.9-33.4) | 22.4 (4.0; 13.9-33.8) |
| Body surface area (m2) | |||
| Median (IQR, range) | 1.6 (0.2; 1.2-2.2) |
1.6 (0.2; 1.3 -2.2) |
1.6 (0.2; 1.2-2.2) |
| ECOG performance status | |||
| 0 | 54 (21.3%) | 69 (27.1%) | 123 (24.2%) |
| 1 | 199 (78.7%) | 186 (72.9%) | 385 (75.8%) |
| EGFR status | |||
| Wild-type | 199 (78.7%) | 198 (77.6%) | 397 (78.1%) |
| Mutant | 54 (21.3%) | 57 (22.4%) | 111 (21.9%) |
| Brain metastases | |||
| Presence | 48 (19.0%) | 52 (20.4%) | 100 (19.7%) |
| Absence | 205 (81.0%) | 203 (79.6%) | 408 (80.3%) |
| Disease stage | |||
| IIIA | 1 (0.4%) | 2 (0.8%) | 3 (0.6%) |
| IIIB | 20 (7.9%) | 31 (12.2%) | 51 (10.0%) |
| IV | 232 (91.7%) | 222 (87.1%) | 454 (89.4%) |
| Smoking status | |||
| Never smoker | 127 (50.2) | 124 (48.6) | 251 (49.4) |
| Smoker | 32 (12.6) | 30 (11.8) | 62 (12.2) |
| Former smoker | 94 (37.2) | 101 (39.6) | 195 (38.4) |
IQR=interquartile range. Data are number of patients (%) or median (IQR). ECOG=Eastern Cooperative Oncology Group.